TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
The purpose of this study is to optimize several multi-dose regimens of otelixizumab,
 determine the highest biologically active dose, evaluate biomarkers and surrogates of
 efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against
 standard safety and efficacy parameters.
Inclusion Criteria:

 -  Adults 12 to 45 years old who are in good general health

 -  Confirmed diagnosis of insulin requiring type 1 diabetes mellitus with good glycemic
 control

 -  Measurable C-peptide levels

 Exclusion Criteria:

 -  Females must not be pregnant or lactating and willing to practice contraception

 -  No prior malignancy, other than non-melanoma skin cancer

 -  Body Mass Index (BMI) > 32 at screening